Data from the phase 1/2 LIBRETTO-001 trial support the FDA approval of selpercatinib in patients with RET fusion-positive thyroid cancer.
Approval Alert | Selpercatinib in RET+ Thyroid Cancer
Data from the phase 1/2 LIBRETTO-121 trial led to the approval of selpercatinib in pediatric RET-mutant thyroid cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI and MRD Take Center Stage on Day 2 of ASCO Breakthrough 2026
2
Pirtobrutinib Earns Positive CHMP Opinion Across All CLL Treatment Lines
3
GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations
4
40 An AI Digital Twin Compares Favorably to Radiologists for Landmark Identification and Measurement in Early-Stage Breast Cancer: A Retrospective, Multi-Institution Clinical Study
5